低分子肝素钠治疗胎儿生长受限的临床研究（临床医学论文资料）.docVIP

低分子肝素钠治疗胎儿生长受限的临床研究（临床医学论文资料） 目录 TOC \o 1-9 \h \z \u 目录 1 正文 1 文1：低分子肝素钠治疗胎儿生长受限的临床研究 1 1 资料与方法 3 2 结果 4 3 讨论 5 文2：低分子肝素钠联合环孢素A醋酸泼尼松治疗原发性肾病综合征临床研究 6 参考文摘引言： 7 原创性声明（模板） 8 文章致谢（模板） 9 正文 低分子肝素钠治疗胎儿生长受限的临床研究（临床医学论文资料） 文1：低分子肝素钠治疗胎儿生长受限的临床研究 Clinical Study of Low Molecular Weight Heparin in Treatment of Fetal Growth Restriction ZHU Qinghua WU Wenxue HAN Qingping Department of Obstetrics and Gynecology， the Peoples Hospital of Pingyang County in Zhejiang Province， Pingyang 325400， China [Abstract] Objective To evaluate the clinical efficacy and safety of low molecular weight heparin in treatment of fetal growth restriction. Methods All 56 pregnant women with FGR were randomly divided into group A and group B， with 28 cases in each. Group A received low molecular weight heparin， and group B received low molecular weight dextran Salvia miltiorrhiza treatment. The pregnant women with preeclampsia were given antispasmodic and antihyperteive treatment. Results The height of the uterus， fetal biparietal diameter， femur length， head circumference， abdominal circumference， umbilical S/D values， changes in the amniotic fluid index， fetal biophysical score， birth weight， neonatal asphyxia of group A and group B were different （P＜）. Platelet count and coagulation paramete of before and after treatment were not significant different （P＞）. Conclusion The low molecular weight heparin helps to improve outcomes of patients with FGR. The low molecular weight heparin has good safety for the mother and fetus. [Key words] Low molecular heparin; Low molecular dextran; Salvia miltiorrhiza; FGR; Neonatal weight 胎儿生长受限（fetal growth restriction，FGR）是严重威胁胎儿发育质量及远期影响儿童和青春期的智能、体能发育的产科并发症[1]，其病因复杂，与胎盘血流灌注不足、遗传、感染、内分泌等多方面因素有关[2]，目前临床上常用补充氨基酸、输注低分子右旋糖酐加丹参来治疗，但疗效甚微。我院通过使用低分子肝素钠改善胎盘血流灌注治疗FGR，取得良好效果，现报道如下。 1 资料与方法 一般资料 选择2007年4月～2009年12月在我院定期产前检查并在我院分娩且确诊为FGR的孕妇56例。诊断标准依据乐杰主编的《妇产科学》（第7版）[3]中的相关标准，患者符合诊断后，根据知情同意的原则，自愿加入研究组，排除标准：①有明确的低分子肝素过敏史或过敏体质者；②患出血性疾病者；③肝功能异常者；④预期24h内手术或分娩